ProMIS Neurosciences Files 8-K on Corporate Governance, Compensation

TL;DR

**ProMIS Neurosciences filed a routine 8-K on corporate governance and compensation, likely a non-event for traders.**

AI Summary

ProMIS Neurosciences Inc. filed an 8-K on January 3, 2024, reporting events that occurred on December 30, 2023. This filing primarily covers routine corporate governance matters under Item 5.02, such as changes in directors or officers and compensatory arrangements, and also includes Regulation FD Disclosure and Financial Statements and Exhibits. For investors, this matters because it signals standard operational updates, but without specific details on personnel changes or compensation, its immediate impact on stock valuation is likely neutral.

Why It Matters

This filing indicates standard corporate updates for ProMIS Neurosciences Inc., which can be important for understanding the company's leadership and financial health, though specific details are not provided in the summary.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting general corporate events without disclosing specific high-impact changes, suggesting low immediate risk.

Analyst Insight

A smart investor would note this routine filing but await more detailed disclosures regarding specific personnel changes or compensatory arrangements before making any investment decisions, as the summary provided is high-level.

Key Players & Entities

• ProMIS Neurosciences Inc. (company) — registrant filing the 8-K
• December 30, 2023 (date) — date of earliest event reported
• January 3, 2024 (date) — date the 8-K was filed
• 001-41429 (other) — Commission File Number for ProMIS Neurosciences Inc.
• Ontario, Canada (other) — jurisdiction of incorporation for ProMIS Neurosciences Inc.

FAQ

Key Financial Figures

• $250,000 — Warma is paid an annual base salary of $250,000 and is eligible for one-time incentive
• $400,000 — incentive cash bonus in an amount up to $400,000 upon the completion of certain mileston

Filing Documents

• pmn-20231230x8k.htm (8-K) — 40KB
• pmn-20231230xex10d1.htm (EX-10.1) — 20KB
• pmn-20231230xex99d1.htm (EX-99.1) — 13KB
• 0001558370-24-000021.txt ( ) — 218KB
• pmn-20231230.xsd (EX-101.SCH) — 4KB
• pmn-20231230_def.xml (EX-101.DEF) — 3KB
• pmn-20231230_lab.xml (EX-101.LAB) — 18KB
• pmn-20231230_pre.xml (EX-101.PRE) — 12KB
• pmn-20231230x8k_htm.xml (XML) — 5KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 3, 2024, the Company issued a press release entitled "ProMIS Neurosciences, Inc. Announces Leadership Transition". A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Employment Agreement between ProMIS Neurosciences Inc. and Mr. Warma, dated as of December 30, 2023 99.1 Press Release, dated January 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROMIS NEUROSCIENCES INC. Date: January 3, 2024 By: /s/ Neil Warma Name: Neil Warma Title: Interim Chief Executive Officer